ENOUGH is pleased to announce the successful completion of a €40 million growth funding round, co-led by World Fund and CPT, aimed at facilitating the expansion of production operations. Notably, prominent former investors such as AXA IM Alts through the Axa Impact Fund, HAL Investments through 280ppm, Onassis Group via Olympic Investments Inc, as well as Tailored Solutions and Scottish Enterprise, have also chosen to reinvest in this initiative. The injection of this new capital elevates ENOUGH’s total raised funds to an impressive sum exceeding €95 million.
Leveraging this substantial influx of funding, the company is poised to amplify its manufacturing capabilities at its Netherlands-based factory. This strategic move directly addresses the surging consumer demand for ABUNDA® mycoprotein. Furthermore, ENOUGH aims to foster internal growth by augmenting its personnel across its offices situated in Glasgow, London, and Sas van Gent.
These strategic endeavors constitute pivotal steps in realizing ENOUGH’s ambitious growth objective of generating one million tonnes of ABUNDA® mycoprotein cumulatively over the ensuing decade. This prodigious output is tantamount to replacing a staggering 5 million cattle or in excess of 1 billion chickens. Such an accomplishment holds the promise of providing sustenance for a progressively burgeoning global populace, while simultaneously combatting the environmentally unsustainable repercussions of conventional protein agriculture.
